New Zealand markets open in 6 hours 9 minutes

Roivant Sciences Ltd. (ROIV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.46+0.10 (+0.97%)
At close: 04:00PM EDT
10.55 +0.09 (+0.86%)
After hours: 07:52PM EDT

Roivant Sciences Ltd.

50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347

Full-time employees904

Key executives

NameTitlePayExercisedYear born
Mr. Matthew GlineCEO & Director1.77MN/A1984
Dr. Eric Venker M.D., Pharm.D.President & COO1.28MN/A1987
Dr. Mayukh Sukhatme M.D.President, Chief Investment Officer & Director1.72MN/A1976
Mr. Richard PulikChief Financial OfficerN/AN/A1979
Ms. Rakhi KumarChief Accounting OfficerN/AN/A1980
Dr. Huafeng Xu Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Jo ChenGeneral CounselN/AN/AN/A
Ms. Kelly GraffHead of PeopleN/AN/AN/A
Ms. Marianne L. RomeoHead of Global Transactions & Risk ManagementN/AN/A1968
Mr. Alex GasnerExecutive Vice President of Roivant HealthN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Corporate governance

Roivant Sciences Ltd.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.